Last reviewed · How we verify
Immunomaintenance therapy
Immunomaintenance therapy is a Small molecule drug developed by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. It is currently in Phase 3 development for Disease maintenance and recurrence prevention (specific indication not publicly detailed).
Immunomaintenance therapy sustains and reinforces immune system function to prevent disease recurrence or progression after initial treatment.
Immunomaintenance therapy sustains and reinforces immune system function to prevent disease recurrence or progression after initial treatment. Used for Disease maintenance and recurrence prevention (specific indication not publicly detailed).
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Immunomaintenance therapy |
|---|---|
| Sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
This approach aims to maintain immune competence and prevent immune exhaustion in patients who have achieved remission or disease control. It typically involves strategies to preserve anti-tumor or anti-disease immunity through continued immune stimulation or support, reducing the risk of relapse.
Approved indications
- Disease maintenance and recurrence prevention (specific indication not publicly detailed)
Common side effects
Key clinical trials
- Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC) (PHASE2)
- A Clinical Study on the Treatment of LACC With Cadonilimab Combined With Chemotherapy Followed by CCRT (PHASE3)
- Tislelizumab in Combination with Chemotherapy ± Radiotherapy for Extensive-Stage Oligometastatic Small Cell Lung Cancer. (PHASE2)
- A Study of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma (PHASE2)
- Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma (PHASE2)
- Low-dose Radiotherapy Combined With Conventional Radiotherapy After Immunotherapy Failure (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Immunomaintenance therapy CI brief — competitive landscape report
- Immunomaintenance therapy updates RSS · CI watch RSS
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology portfolio CI
Frequently asked questions about Immunomaintenance therapy
What is Immunomaintenance therapy?
How does Immunomaintenance therapy work?
What is Immunomaintenance therapy used for?
Who makes Immunomaintenance therapy?
What development phase is Immunomaintenance therapy in?
Related
- Manufacturer: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Disease maintenance and recurrence prevention (specific indication not publicly detailed)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing